- Home
- AARD vs ALLO Comparison
AARD vs ALLO Comparison
Compare AARD & ALLO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AARD
- ALLO
- Stock Information
- Founded
- AARD 2017
- ALLO 2017
- Country
- AARD United States
- ALLO United States
- Employees
- AARD N/A
- ALLO N/A
- Industry
- AARD Biotechnology: Pharmaceutical Preparations
- ALLO Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- AARD Health Care
- ALLO Health Care
- Exchange
- AARD Nasdaq
- ALLO Nasdaq
- Market Cap
- AARD 231.9M
- ALLO 252.9M
- IPO Year
- AARD 2025
- ALLO 2018
- Fundamental
- Price
- AARD $9.91
- ALLO $1.24
- Analyst Decision
- AARD Strong Buy
- ALLO Buy
- Analyst Count
- AARD 8
- ALLO 11
- Target Price
- AARD $30.63
- ALLO $8.67
- AVG Volume (30 Days)
- AARD 162.6K
- ALLO 2.4M
- Earning Date
- AARD 11-13-2025
- ALLO 11-06-2025
- Dividend Yield
- AARD N/A
- ALLO N/A
- EPS Growth
- AARD N/A
- ALLO N/A
- EPS
- AARD N/A
- ALLO N/A
- Revenue
- AARD N/A
- ALLO N/A
- Revenue This Year
- AARD N/A
- ALLO N/A
- Revenue Next Year
- AARD N/A
- ALLO $100.00
- P/E Ratio
- AARD N/A
- ALLO N/A
- Revenue Growth
- AARD N/A
- ALLO N/A
- 52 Week Low
- AARD $4.88
- ALLO $0.86
- 52 Week High
- AARD $19.58
- ALLO $3.78
- Technical
- Relative Strength Index (RSI)
- AARD 39.27
- ALLO 52.74
- Support Level
- AARD $9.34
- ALLO $1.15
- Resistance Level
- AARD $11.51
- ALLO $1.28
- Average True Range (ATR)
- AARD 0.85
- ALLO 0.08
- MACD
- AARD -0.01
- ALLO 0.01
- Stochastic Oscillator
- AARD 20.39
- ALLO 74.07
About AARD Aardvark Therapeutics Inc.
Aardvark Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. It is focused on on developing selective compounds, targeting Bitter Taste Receptors (TAS2Rs) for hunger-associated conditions. Its product candidate, ARD-101, is an oral gut-restricted small-molecule agonist of certain TAS2Rs expressed in the gut lumen for which have initiated a Phase 3 clinical trial for hyperphagia associated with PWS.
About ALLO Allogene Therapeutics Inc.
Allogene Therapeutics Inc is a clinical-stage biotech firm specializing in immuno-oncology, focusing on the development of genetically engineered allogeneic T-cell products for cancer and autoimmune diseases. Their pipeline includes off-the-shelf T-cell candidates designed to target cancer cells or autoreactive cells in autoimmune disorders. Notably, their allogeneic approach, derived from healthy donors, allows for broader patient eligibility and scalability. With a vision to redefine CAR T therapy, the company concentrates on core programs targeting lymphoma, leukemia, autoimmune diseases, and solid tumors. Revenue, generated from collaborations and licensing agreements, supports their research and development efforts.